Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna specialty medication dosing limits — Coverag…
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Medical Specialty Medication Quantity Limits — Maximum Dosing Regimens

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists medications with associated diagnoses and maximum dosing regimens for specialty medications relevant to immunology/rheumatology and related conditions; applies to Aetna medical specialty medication quantity limits.

    Policy Summary
    PayerAetna
    PolicyMedical Specialty Medication Quantity Limits — Maximum Dosing Regimens
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionRequest prior authorization consistent with the diagnosis‑specific maximum dosing regimen and document the diagnosis, patient weight/age, and planned dosing schedule.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+medication entries (partial document)
    1/1/2026effective date stated for many entries
    weight‑based dosingmany regimens specified as mg/kg
    age/weight bandsage/weight strata common

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria — Maximum Dosing Regimens

    Actemra (Tocilizumab) — Initial/Maximum dosing

    Covered when dosing does not exceed the listed maximum dosing regimens for the specified diagnosis:

    Actemra (Tocilizumab) dosing examples: Acute Graft Versus Host Disease: IV 8 mg/kg every 2 weeks; Castleman disease (unicentric or multicentric): IV 8 mg/kg every 2 weeks; Cytokine Release Syndrome (CRS): IV ≥2 years <30 kg 12 mg/kg (up to 800 mg) no more than 4 total doses at least 8 hours apart; ≥30 kg 8 mg/kg (up to 800 mg) no more than 4 total doses at least 8 hours apart; Giant Cell Arteritis: IV ≥18 years 6 mg/kg (up to 600 mg) every 4 weeks; Immune checkpoint inhibitor-related toxicities: IV 8 mg/kg every 4 weeks; Polyarticular/oligoarticular JIA: IV ≥2 years <30 kg 10 mg/kg every 4 weeks, ≥30 kg 8 mg/kg every 4 weeks; Polymyalgia rheumatica: IV 8 mg/kg every 4 weeks; Rheumatoid arthritis: IV ≥18 years 8 mg/kg (up to 800 mg) every 4 weeks; Systemic JIA: IV ≥2 years <30 kg 12 mg/kg every 2 weeks, ≥30 kg [weight-based regimen per product entry]weight and age-based dosing specified

    Sourced from document entries for Actemra (Tocilizumab) (chunks 0–1)

    Adcetris (Brentuximab vedotin) — Maximum dosing

    Covered when dosing does not exceed the listed maximum dosing regimens for the specified diagnosis:

    Adcetris (Brentuximab vedotin) dosing: For CD30+ lymphomas and select B‑cell/T‑cell lymphomas: IV 1.8 mg/kg (up to 180 mg) every 3 weeks; for classical Hodgkin lymphoma (adult): IV 1.2 mg/kg (up to 120 mg) every 2 weeks OR 1.5 mg/kg (up to 150 mg) on days 1 and 8 of a 21‑day cycle for 2 cycles (per indication-specific entries).per‑diagnosis dose and frequency

    Sourced from Adcetris entries in document (chunks 1–2)

    Alyglo (Immune Globulin IV) — Multiple indications and dosing limits

    Covered when dosing matches the listed IVIG maximum regimens for the specific diagnosis and product:

    Alyglo (IVIG) — selected indications and dosing: Examples: CIDP — initial 2 g/kg divided over 2–5 days then maintenance 1 g/kg divided over 1–2 days every 3 weeks; Guillain‑Barré syndrome — 2 g/kg divided over 1–5 days; HSCT/BMT support — 800 mg/kg every week; Measles prophylaxis — 400 mg/kg once within 6 days (or 10 days per some products) after exposure; Neonatal hemochromatosis prophylaxis (maternal) — 1 g/kg IV weekly from week 18 until delivery; Multiple myeloma support — 800 mg/kg every 3 weeks; many autoimmune, neurologic, infectious, and transplant indications have specific per‑diagnosis IV regimens as listed for Alyglo and peer products.dose per kg and frequency vary by indication; see product-specific entries

    Sourced from Alyglo and related IVIG product entries (chunks 3–12)

    Alymsys (Bevacizumab-maly) — Maximum dosing

    Covered when dosing does not exceed the listed maximum regimens for the diagnosis and route:

    Alymsys (Bevacizumab-maly) dosing: Oncology IV examples: ampullary adenocarcinoma IV 5 mg/kg every 2 weeks; many solid tumors IV 15 mg/kg every 3 weeks or IV 10 mg/kg every 2 weeks depending on indication; intravitreal ophthalmic examples: diabetic macular edema/DR intravitreal 1.5 mg every 4 weeks, neovascular AMD intravitreal 1.25 mg every 4 weeks (or 2.5 mg for specific regimens), retinopathy of prematurity intravitreal 0.625 mg single dose for pediatric patients.per‑indication regimen specified

    Sourced from Alymsys entries (chunks 12–16)

    Aralast NP / Asceniv — Maximum dosing

    Covered when dosing follows the listed maximum regimens for the specified diagnosis:

    Aralast NP — dosing examples: Acute GVHD: IV 60 mg/kg twice weekly for up to 8 doses; Alpha‑1 antitrypsin deficiency (adults ≥18 years): IV 60 mg/kg weekly.60 mg/kg dosing as indicated

    Sourced from Aralast NP entries (chunk 17)

    Asceniv — IVIG examples: Multiple indications mirror other IVIG products: e.g., CIDP initial 2 g/kg divided over 2–5 days then maintenance 1 g/kg every 3 weeks; HSCT/BMT support 800 mg/kg every week; many autoimmune and transplant indications have product‑specific mg/kg regimens listed.per‑indication dose and frequency

    Sourced from Asceniv entries (chunks 17–19)

    Coverage by product and diagnosis (examples)

    Covered when ALL of the following are met:

    Dose within listed maximum: Requested dose, frequency, route, and regimen must be at or below the maximum dosing regimen specified for the medication and diagnosis (including age/weight strata and induction/maintenance distinctions).as listed per product and diagnosis

    See product-specific entries for exact numeric limits

    Diagnosis match: The indication/diagnosis must match one of the diagnoses listed for the product in the document segment (e.g., Crohn's disease, ulcerative colitis, rheumatoid arthritis, CIDP).exact diagnosis listed

    Entries include many specific diagnoses per product

    Age/weight criteria: Patient age and weight must fall into the strata specified for the dosing regimen (e.g., <30 kg vs ≥30 kg; <56 kg, 56–<86 kg, ≥86 kg; pediatric vs adult bands).

    Covered when ALL of the following are met

    Coverage is bounded by the listed maximum dosing regimens for each product and diagnosis; coverage for a request requires that dosing and frequency do not exceed the specified limits for the patient’s age/weight and diagnosis.

    Dose within listed maximum: Requested dose, frequency, route, and regimen must be at or below the maximum dosing regimen specified for the medication and diagnosis (including age/weight strata and induction/maintenance distinctions).as listed per product and diagnosis

    See product-specific entries for exact numeric limits

    Diagnosis match: The indication/diagnosis must match one of the diagnoses listed for the product in the document segment.exact diagnosis listed

    Entries include many specific diagnoses per product

    Age/weight criteria: Patient age and weight must fall into the strata specified for the dosing regimen (e.g., CRS dosing for tocilizumab: <30 kg vs ≥30 kg; IV ustekinumab weight tiers).

    Quantity limits by medication and diagnosis (partial list)

    Covered when dosing does not exceed the listed maximum dosing regimen for the specified diagnosis.

    Bivigam - Secondary immunosuppression: Route: Intravenous; Maximum dosing regimen: 800 mg/kg every 3 weeks.800 mg/kg q3w

    Sourced from Bivigam entry (chunk 54)

    Bivigam - Solid organ transplantation (allosensitized): Route: Intravenous; Maximum dosing regimen: 3 g/kg divided over 2–5 days (max 1 g/kg/day) every 2–4 weeks.3 g/kg per course; max 1 g/kg/day

    Sourced from Bivigam entries (chunk 55)

    Bivigam - Stevens-Johnson Syndrome / TEN: Route: Intravenous; Maximum dosing regimen: 3 g/kg divided over 1–5 consecutive days; repeat if needed.3 g/kg per course

    Covered when dosing within listed maximums

    Covered when dosing and frequency do not exceed the listed maximum dosing regimens for the specified diagnosis

    Cyramza (Ramucirumab) — example: Hepatocellular carcinoma: IV 8 mg/kg every 2 weeks.8 mg/kg q2w

    Sourced from Cyramza entry (chunk 72)

    Darzalex (Daratumumab) — example: Multiple myeloma/POEMS: IV 16 mg/kg per dose (schedule varies by regimen). Darzalex Faspro (SC): 1800/30,000 mg‑units per dose per schedule.16 mg/kg IV or 1800/30,000 mg‑units SC per dosing schedule

    Sourced from Darzalex entries (chunks 72–73)

    Dysport / Daxxify — example: Daxxify (cervical dystonia): IM ≥18 years 250 Units divided among affected muscles; Dysport upper/lower limb spasticity: ≥18 years 1500 Units total per treatment, retreat no sooner than every 12 weeks (pediatric rules apply).per‑indication unit limits; q12w min

    Covered when dosing matches the specified product/indication maximum regimens

    Covered when dosing matches the specified product/indication maximum regimens:

    General IVIG rule: Use the listed maximum dosing regimen for the specified IVIG product and diagnosis (dose per kg, route, frequency, and any age-based or weight-based adjustments). For CIDP, example: initial 2 g/kg divided over 2–5 days; maintenance 1 g/kg divided over 1–4 days every 3 weeks.see individual entries

    Sourced from Gammagard and related IVIG entries (chunks 97,101)

    Selected indication-specific maximum regimens

    Examples of indication-specific maximum regimens (not exhaustive):

    Solid organ transplant (allosensitized): Gammagard Liquid: 3 g/kg divided over 2–5 days (max 1 g/kg/day) every 2–4 weeks.3 g/kg total per course

    Effective 1/1/2026 (chunk 104)

    Stevens-Johnson Syndrome/TEN: Gammagard Liquid: 3 g/kg divided over 1–5 consecutive days; repeat if needed.3 g/kg total per course

    Effective 1/1/2026 (chunk 104)

    CIDP: Gammagard Liquid: Initial 2 g/kg divided over 2–5 days; Maintenance 1 g/kg divided over 1–4 days every 3 weeks.Initial 2 g/kg; maintenance 1 g/kg q3w

    Effective 1/1/2026 (chunk 97)

    Diagnosis-specific maximum dosing regimens (quantity limits)

    Covered when dosing does not exceed the following maximum regimens for the specified diagnosis and product:

    Sample IVIG per-diagnosis entries: (Representative examples drawn from multiple IVIG products) — Churg‑Strauss: IV 2 g/kg divided over 2–5 days q3w; Dermatomyositis: IV 2 g/kg divided over 1–5 days q4w; Guillain‑Barré: IV 2 g/kg divided over 1–5 days; ITP: IV 1 g/kg once (may repeat) or 400 mg/kg daily x5; Kawasaki syndrome (pediatric): various product entries list 2 g/kg single dose or 400 mg/kg daily x4; Measles prophylaxis: 400 mg/kg once within exposure window; Primary immunodeficiency: 800 mg/kg every 3 weeks; many other diagnoses have explicit mg/kg and schedule limits as listed per product entries.per product/diagnosis regimens as listed

    Sourced from multiple IVIG product chunks (108–127)

    Covered indications with quantity limits

    Covered when dosing does not exceed the specified maximum dosing regimen for the listed diagnosis:

    Per-diagnosis dosing entries (summary): Each listed diagnosis has an associated maximum dosing regimen (weight‑based and frequency); coverage follows those maximums per diagnosis and product (examples include 2 g/kg divided over 2–5 days for many autoimmune conditions; 400 mg/kg once for measles prophylaxis; 800 mg/kg every 3 weeks for primary immunodeficiency).see per‑diagnosis entries

    Sourced from IVIG and related entries (chunks 126,145)

    Selected dosing limits (Gamunex-C)

    Maximum dosing regimens by medication and diagnosis (examples from excerpt):

    Gamunex‑C: Rasmussen Encephalitis: Intravenous 400 mg/kg every 2 weeks.400 mg/kg q2w

    Effective 1/1/2026 (chunk 144)

    Gamunex‑C: Renal Transplantation (ABO incompatibility/positive crossmatch): Intravenous 400 mg/kg daily for 5 days every 4 weeks.400 mg/kg daily x5 q4w

    Effective 1/1/2026 (chunk 144)

    Gamunex‑C: Stevens‑Johnson Syndrome/TEN: Intravenous 3 g/kg divided over 2–5 days (max 1 g/kg/day) every 2–4 weeks or as specified.3 g/kg divided over 2–5 days

    Effective 1/1/2026 (chunk 144)

    Selected dosing limits (other immunoglobulins)

    Additional examples — immunoglobulins and other agents:

    Gamunex‑C: Systemic Lupus Erythematosus: Intravenous 2 g/kg divided over 2–5 consecutive days every 4 weeks.2 g/kg q4w

    Sourced from Gamunex‑C entry (chunk 146)

    Hizentra: Primary Immunodeficiency: Subcutaneous 365 mg/kg every week (based on maximum IVIG equivalence of 800 mg/kg q3w).365 mg/kg weekly

    Sourced from Hizentra/other SC IG entries (chunk 146)

    Hyqvia: Primary Immunodeficiency: Subcutaneous 800 mg/kg every 3 weeks after initial ramp‑up.800 mg/kg q3w

    Sourced from Hyqvia entry (chunk 146)

    Selected biologic dosing limits

    Examples — selected biologic dosing limits:

    Trastuzumab products (Herceptin/Hercessi/Herzuma/Ogivri) — example: IV initial/maintenance schedules vary by product and cycle (examples: initial 4 mg/kg then 2 mg/kg weekly; or 8 mg/kg once then 6 mg/kg every 3 weeks); intrathecal/intraventricular dosing for leptomeningeal disease 150 mg weekly for some preparations.product‑ and indication‑specific regimens

    Sourced from trastuzumab entries (chunk 151)

    Imuldosa IV (Ustekinumab) — weight-tiered IV dosing: IV single‑dose weight tiers for selected indications: <56 kg = 260 mg once; 56–<86 kg = 390 mg once; ≥86 kg = 520 mg once.weight bands as listed

    Sourced from Imuldosa/Imuldosa IV entry (chunk 156)

    Inflectra dosing limits

    Infliximab biosimilar dosing examples and limits:

    Inflectra (Infliximab‑dyyb) — Crohn's disease: Initial: 5 mg/kg on weeks 0, 2, and 6; Maintenance: 5 mg/kg every 8 weeks. Maximum induction: 10 mg/kg on weeks 0, 2, and 6 then every 8 weeks; maximum maintenance up to 10 mg/kg every 4–8 weeks for incomplete response.induction and maintenance dosing per entry

    Sourced from Inflectra entries (chunks 160–161)

    Inflectra — Rheumatoid arthritis and other indications: RA initial: 3 mg/kg on weeks 0, 2, and 6; maintenance 3 mg/kg every 8 weeks; maximum maintenance dosing 10 mg/kg every 4 weeks for select indications.as listed per indication

    Sourced from Inflectra entries (chunks 160–161)

    Product-specific maximum dosing regimens (partial)

    Covered when dosing does not exceed the listed Maximum Dosing Regimen for the specified diagnosis and product.

    Inflectra (Infliximab-dyyb) — Ulcerative Colitis: Initial: 5 mg/kg on weeks 0, 2, and 6; Maintenance: 5 mg/kg every 8 weeks; Maximum induction: 10 mg/kg on weeks 0, 2, and 6 then every 8 weeks. For ≥6 to <18 years similar initial/maintenance; maximum maintenance 10 mg/kg every 8 weeks; 10 mg/kg every 4 weeks for incomplete response.age‑specific as listed

    Sourced from Inflectra entries (chunk 162)

    Inflectra — Uveitis: IV 10 mg/kg every 4 weeks (may include induction doses on weeks 0,2,6).10 mg/kg q4w

    Sourced from Inflectra entries (chunk 162)

    Bevacizumab products (Jobevne, Mvasi) — oncology and ophthalmology

    Covered when dosing is within the listed maximum regimens per indication.

    Jobevne (Bevacizumab-nwgd) — sample regimens: Oncology: IV 5 mg/kg q2w (ampullary adenocarcinoma), IV 15 mg/kg q3w (cervical cancer, HCC support), IV 10 mg/kg q2w or 15 mg/kg q3w for CNS cancers; Ophthalmology intravitreal: DME 1.5 mg q4w; neovascular AMD intravitreal 1.25 mg q4w or 2.5 mg q4w for specified regimens; ROP pediatric: 0.625 mg single dose.age‑ and indication‑specific as listed

    Sourced from Jobevne/Mvasi entries (chunks 163,166,181)

    Mvasi (Bevacizumab-awwb) — parallel regimens: Parallels Jobevne dosing: IV 5 mg/kg q2w, IV 15 mg/kg q3w, intravitreal 1.5 mg q4w for DME among other indication‑specific regimens.as listed per indication

    Sourced from Mvasi entries (chunk 181)

    Other oncology biologics (Denosumab, Kadcyla, Kanjinti)

    Covered when dosing is within the listed maximum regimens per indication.

    Jubbonti (Denosumab-bbdz): Subcutaneous 60 mg every 6 months for breast cancer, osteoporosis, and prostate cancer indications.60 mg q6 months

    Sourced from Jubbonti entry (chunk 167)

    Kadcyla (Ado-trastuzumab emtansine): IV 3.6 mg/kg every 3 weeks for approved oncology indications.3.6 mg/kg q3w

    Sourced from Kadcyla entry (chunk 167–168)

    Kanjinti (Trastuzumab-anns): Multiple initial/maintenance schedules by cycle length (examples: initial 4 mg/kg then 2 mg/kg weekly; or 8 mg/kg once then 6 mg/kg q3w); allowed up to 52 weeks for adjuvant/neoadjuvant uses; intrathecal dosing for leptomeningeal disease 150 mg weekly for some entries.treatment‑duration and schedule limits noted

    Keytruda (Pembrolizumab) — broad oncology indications

    Covered when dosing does not exceed the listed maximum regimens for the specific diagnosis and age group.

    Keytruda (Pembrolizumab) — adult dosing: IV 200 mg every 3 weeks or 400 mg every 6 weeks for many adult indications.standard adult regimens

    Sourced from Keytruda entries (chunks 170,175)

    Keytruda — pediatric/weight‑based dosing: For pediatric indications: 2 mg/kg every 3 weeks (up to a maximum of 200 mg) for certain <18 year indications; age/weight caps apply per indication.2 mg/kg q3w up to 200 mg cap

    Sourced from Keytruda pediatric entries (chunk 176)

    Ophthalmology biologics (Lucentis / Ranibizumab)

    Covered when dosing is within the listed intravitreal regimens.

    Lucentis (Ranibizumab) — ophthalmic regimens: Diabetic macular edema/diabetic retinopathy: intravitreal 0.3 mg per affected eye every ~28 days; Macular edema after RVO: intravitreal 0.5 mg per affected eye every ~28 days; Neovascular AMD: 0.5 mg per affected eye every month (may dose less frequently after 3–4 monthly doses); myopic CNV: 0.5 mg monthly for up to 3 months with retreatment as needed.frequency limits per indication

    Sourced from Lucentis entries (chunks 180–181)

    Lemtrada (Alemtuzumab)

    Covered when dosing follows the listed course schedule for multiple sclerosis.

    Lemtrada (Alemtuzumab): First course: IV 12 mg daily for 5 consecutive days; Subsequent course(s): IV 12 mg daily for 3 consecutive days, administered 12 months after the last dose of the prior course.course schedules as listed

    Sourced from Lemtrada entry (chunk 180)

    Maximum dosing per diagnosis

    Coverage is limited to the maximum dosing regimens specified for each medication and diagnosis.

    Dose/frequency/route must not exceed listed maximum: Prescribed dose, route, and frequency must be within the medication‑specific maximum dosing regimen listed for the stated diagnosis; exceeding those limits may require prior authorization or be subject to denial.see individual medication entries

    Sourced from multiple product entries and policy framing (chunks 180,181,187,191)

    Representative examples: Examples include Lemtrada IV first course 12 mg x5 days; Lucentis intravitreal 0.3–0.5 mg monthly depending on indication; Neulasta weight/age‑based dosing for febrile neutropenia or ARS; infliximab/rituximab dosing limits across indications (detailed in product sections).medication-specific

    Representative entries summarized from document (chunks 180,181,187,191)

    Maximum dosing regimens (per medication and indication)

    Coverage is framed as allowed up to the following maximum dosing regimens for each medication/diagnosis pair:

    Octagam/other IVIG examples: Stevens‑Johnson Syndrome/TEN: IV 3 g/kg divided over 1–5 days (repeat if needed); Stiff‑Person Syndrome: IV 2 g/kg divided over 2–5 days monthly; SLE: IV 2 g/kg divided over 2–5 days q4w; Varicella prophylaxis: IV 400 mg/kg once within exposure window. General IVIG maximum regimen examples displayed across multiple products.per‑indication dosing limits

    Sourced from Octagam/IVIG entries (chunks 198–200)

    Trastuzumab biosimilars (Ogivri/others): Breast/colorectal/gastric/hepatobiliary/CNS/leptomeningeal regimens: IV initial/maintenance dosing such as initial 4 mg/kg then 2 mg/kg weekly; or 8 mg/kg then 6 mg/kg q3w; intrathecal/intraventricular 150 mg weekly for leptomeningeal disease in some entries.indication-specific regimens

    Sourced from Ogivri and biosimilar entries (chunks 200–202)

    Opdivo (Nivolumab):

    Orencia (Abatacept) — diagnosis-specific dosing limits

    Covered when dosing follows the listed maximum regimens for the specified diagnoses and age/weight bands.

    Orencia — Acute GVHD prophylaxis: IV ≥6 years: 10 mg/kg (up to 1000 mg) on day -1, then on days 5, 14, and 28 after transplant; 2 to <6 years: 15 mg/kg on day -1 then 12 mg/kg on days 5, 14, 28.age and schedule specified

    Sourced from Orencia entry (chunk 216)

    Orencia — Chronic GVHD: IV initial 10 mg/kg on weeks 0, 2, and 4; maintenance 10 mg/kg every 4 weeks.schedule specified

    Sourced from Orencia entry (chunk 216)

    Orencia — Immune checkpoint inhibitor toxicity: IV 10 mg/kg every 2 weeks.schedule specified

    Osenvelt (Denosumab-bmwo) / Ospomyv (Denosumab-dssb) — dosing by indication

    Covered when dosing matches diagnosis‑specific maximum regimens.

    Osenvelt — Giant Cell Tumor of Bone / Hypercalcemia / Palliative bone metastases: SC 120 mg on days 1, 8, and 15 of month 1 then 120 mg every 4 weeks for indicated oncologic skeletal uses.120 mg loading then q4w

    Sourced from Osenvelt entries (chunks 218–219)

    Osenvelt — Mastocytosis-related osteopenia/osteoporosis: SC 60 mg every 6 months.60 mg q6 months

    Sourced from Osenvelt entry (chunk 218)

    Ospomyv — Breast cancer/osteoporosis/prostate cancer: SC 60 mg every 6 months (product biosimilar dosing for osteoporosis/oncologic prevention of skeletal events).60 mg q6 months

    Otulfi (Ustekinumab-aauz) IV/SC — Crohn's, Ulcerative colitis, plaque psoriasis, psoriatic arthritis, immune-related toxicity

    Covered when dosing follows indicated route and weight bands or schedules.

    Otulfi IV — Crohn's, UC, immune toxicities: IV single‑dose weight bands: <56 kg 260 mg once; 56–<86 kg 390 mg once; ≥86 kg 520 mg once (applies to Crohn's, UC, and immune checkpoint inhibitor‑related toxicity IV dosing where specified).weight bands

    Sourced from Otulfi/Pyzchiva/Pyzchiva IV entries (chunks 220–221,246)

    Otulfi SC — Crohn's disease: SC ≥18 years: 90 mg every 8 weeks; may dose 90 mg every 4 weeks for incomplete response.90 mg q8w (q4w if incomplete response)

    Sourced from Otulfi SC entries (chunk 221)

    Otulfi SC — Plaque Psoriasis / Psoriatic Arthritis: Plaque psoriasis ≥18 years <101 kg: initial 45 mg on weeks 0 and 4 then 45 mg every 12 weeks; psoriatic arthritis similar initial 45 mg wks 0 and 4 then 45 mg q12w; pediatric/adolescent weight bands noted for ≥6 years cohorts with specified initial/maintenance dosing.

    Panzyga (Immune Globulin Intravenous) — multiple immunologic and transplant indications

    Covered when dosing matches the listed indication‑specific intravenous dosing regimens (weight‑ and schedule‑based).

    Panzyga — CIDP: Initial: 2 g/kg divided over 2 consecutive days every 3 weeks; Maintenance: 1 g/kg divided over 1–2 days every 3 weeks.schedule specified

    Sourced from Panzyga entries (chunks 223–225)

    Panzyga — Guillain‑Barré Syndrome: IV 2 g/kg divided over 1–5 consecutive days per treatment course.2 g/kg per course

    Sourced from Panzyga entries (chunks 225–226)

    Panzyga — HSCT/BMT support: 800 mg/kg every week (per product entry for transplant support).800 mg/kg weekly

    Pavblu (Aflibercept-ayyh) — ophthalmic indications

    Covered when injected intravitreally per the listed initial and maintenance schedules for diabetic macular edema, diabetic retinopathy, and neovascular AMD.

    Pavblu — Diabetic Macular Edema / Diabetic Retinopathy: Intravitreal 2 mg per affected eye every 4 weeks for 5 initial doses; Maintenance: 2 mg every 4 weeks (approx. every 25 days).2 mg q4w initial x5 then q4w maintenance

    Sourced from Pavblu entries (chunks 233–234)

    Pavblu — Neovascular (wet) AMD: Intravitreal initial 2 mg per affected eye every 4 weeks for first 3 months; Maintenance: 2 mg every 4 weeks thereafter.2 mg q4w initial then q4w maintenance

    Sourced from Pavblu entry (chunk 235)

    Perjeta (Pertuzumab) — oncology indications

    Covered when administered intravenously per the listed initial and maintenance dosing schedule for multiple tumor types.

    Perjeta — oncology dosing: Initial: IV 840 mg once; Maintenance: IV 420 mg every 3 weeks for biliary tract cancer, breast cancer, colorectal cancer, salivary gland tumors and other listed tumor types.840 mg initial; 420 mg q3w maintenance

    Sourced from Perjeta entries (chunk 235)

    Example single-medication coverage nodes

    Covered when dosing does not exceed the following maximum regimens (per medication and indication):

    Pavblu (Aflibercept-ayyh) - Neovascular AMD: Intravitreal: Initial 2 mg per affected eye every 4 weeks for first 3 months; Maintenance 2 mg per affected eye every 4 weeks.2 mg every 4 weeks

    Effective 1/1/2026 (chunk 235)

    Perjeta (Pertuzumab) - multiple cancers: Intravenous: Initial 840 mg once; Maintenance 420 mg every 3 weeks.840 mg initial, 420 mg q3w maintenance

    Sourced from Perjeta entry (chunk 235)

    Privigen (IVIG) dosing by indication

    Privigen dosing limits by diagnosis (representative examples):

    Privigen dosing entries (examples): Multiple diagnosis‑specific regimens provided: e.g., 2 g/kg divided over 2–5 days; 1 g/kg per day; 400 mg/kg every 3 weeks; 800 mg/kg weekly for HSCT/BMT support; 500 mg/kg every 4 weeks for hypogammaglobulinemia post CAR‑T; CIDP initial 2 g/kg then maintenance 1 g/kg q3w; Kawasaki syndrome <18 years 2 g/kg single dose.varies by indication; see specific entry

    Sourced from Privigen entries (chunks 236–245)

    Prolastin-C and Prolia

    Other immunoglobulin and specialty product limits (examples):

    Prolastin‑C: IV 60 mg/kg twice weekly for up to 8 doses for acute GVHD; maintenance 60 mg/kg weekly for alpha‑1 antitrypsin deficiency adults.60 mg/kg per schedule

    Sourced from Prolastin‑C entry (chunk 245)

    Prolia (Denosumab): SC 60 mg every 6 months for osteoporosis and specified cancer‑related indications.60 mg q6 months

    Sourced from Prolia entry (chunk 245)

    Pyzchiva dosing

    Pyzchiva IV/SC dosing by indication and weight bands:

    Pyzchiva IV — weight‑tier induction: IV single‑dose weight tiers: <56 kg 260 mg once; 56–<86 kg 390 mg once; ≥86 kg 520 mg once for Crohn’s, UC, and immune checkpoint inhibitor–related toxicities where IV induction is specified.see weight bands

    Sourced from Pyzchiva IV entries (chunk 246)

    Pyzchiva SC — maintenance: Adults: 90 mg every 8 weeks; may increase to 90 mg every 4 weeks for incomplete response; pediatric weight‑based initial and maintenance regimens specified for certain indications.90 mg q8w (q4w for incomplete response)

    Sourced from Pyzchiva SC entries (chunks 247–248)

    Infliximab (Remicade) and Renflexis dosing

    Remicade and Renflexis dosing limits by indication:

    Remicade / Renflexis — Acute GVHD: IV 10 mg/kg every week (acute GVHD indication).10 mg/kg weekly

    Sourced from Remicade/Renflexis entries (chunks 249,253)

    Infliximab — Ankylosing spondylitis / axial spondyloarthritis: Adults: Initial 5 mg/kg on weeks 0, 2, and 6; Maintenance 5 mg/kg every 6 weeks; maximum maintenance 7.5 mg/kg every 4 weeks (Renflexis lists similar limits).induction then maintenance with max maintenance limits

    Sourced from Remicade/Renflexis entries (chunks 250,253)

    Infliximab — Crohn's disease: Pediatric/adult induction 5 mg/kg on weeks 0, 2, and 6; Maintenance 5 mg/kg every 8 weeks; maximum induction/maintenance up to 10 mg/kg for certain scenarios; 10 mg/kg every 4 weeks for incomplete response in adults per product entries.

    Infliximab products (Remicade) dosing by diagnosis

    Maximum dosing regimens for Remicade (Infliximab) by diagnosis:

    Remicade — Rheumatoid Arthritis: IV adults ≥18 years: Initial 3 mg/kg on weeks 0, 2, and 6; Maintenance 3 mg/kg every 8 weeks; Maximum maintenance dose 10 mg/kg every 4 weeks.max maintenance 10 mg/kg q4w

    Sourced from Remicade entry (chunk 252)

    Remicade — Sarcoidosis / Takayasu's arteritis / Uveitis: IV 10 mg/kg every 4 weeks (may include induction weeks 0,2,6) per diagnosis‑specific entries.10 mg/kg q4w

    Sourced from Remicade entry (chunk 252)

    Remicade — Ulcerative Colitis: Ages ≥6 to <18: initial 5 mg/kg on weeks 0,2,6; maintenance 5 mg/kg q8w; max induction 10 mg/kg on weeks 0,2,6 then q8w. Ages ≥18 similar with max maintenance up to 10 mg/kg q8w; incomplete response dosing up to 10 mg/kg more frequently as specified.

    Infliximab biosimilar (Renflexis) dosing by diagnosis

    Maximum dosing regimens for Renflexis (Infliximab‑abda) by diagnosis:

    Renflexis — Acute GVHD: IV 10 mg/kg every week.10 mg/kg weekly

    Sourced from Renflexis entry (chunk 253)

    Renflexis — Ankylosing spondylitis/axial spondyloarthritis: Adults: initial 5 mg/kg on weeks 0,2,6; maintenance 5 mg/kg every 6 weeks; maximum maintenance 7.5 mg/kg every 4 weeks.max maintenance 7.5 mg/kg q4w

    Sourced from Renflexis entry (chunk 253)

    Renflexis — Crohn's disease: Ages ≥6 to <18 and ≥18 similar induction 5 mg/kg weeks 0,2,6 with maintenance 5 mg/kg q8w; maximum induction 10 mg/kg on weeks 0,2,6 then q8w; maximum maintenance up to 10 mg/kg q8w; 10 mg/kg q4w for incomplete response per product entries.up to 10 mg/kg q4w for incomplete response

    Riabni (rituximab-arrx) dosing by diagnosis

    Maximum dosing regimens for Riabni (rituximab‑arrx) across hematologic, autoimmune, neurologic, and transplant‑related indications (Effective 1/1/2026 for many entries):

    Allogeneic transplant conditioning: IV: 375 mg/m² on the day before transplant and 1000 mg/m² on days 1, 8, and 15 after transplant.specified schedule

    Sourced from Riabni entry (chunk 256)

    Autoimmune hemolytic anemia / ITP / TTP: IV: 375 mg/m² (frequency varies); for ITP/TTP example: 375 mg/m² weekly for 4 doses.375 mg/m² typical; ITP 4 weekly doses

    Sourced from Riabni entries (chunks 257,262)

    CNS primary lymphoma / intrathecal use: IV: 750 mg/m² every week for primary CNS lymphoma; intrathecal/intraventricular dosing example: 25 mg (not more frequent than twice weekly) for leptomeningeal use.750 mg/m² weekly; IT ≤ twice weekly

    Rituxan (rituximab) dosing by diagnosis

    Maximum dosing regimens for Rituxan (rituximab) across hematologic, autoimmune, neurologic, dermatologic, and transplant indications (many entries mirror Riabni dosing):

    Allogeneic transplant conditioning: IV: 375 mg/m² on the day before transplant and 1000 mg/m² on days 1, 8, and 15 after transplant.specified schedule

    Sourced from Rituxan entries (chunk 266)

    Autoimmune hemolytic anemia; B‑cell ALL; B‑cell lymphomas: IV: 375 mg/m² typical dosing (frequency varies; generally should not be more frequent than once weekly); other regimens include 500 mg/m² or 1000 mg doses depending on diagnosis.375 mg/m² typical; alternative regimens noted

    Sourced from Rituxan entries (chunks 266–269)

    GPA/MPA: IV: ≥18 years: 375 mg/m² weekly x4, then 500 mg every 2 weeks x2 (start no sooner than 16–24 weeks after last induction), then 500 mg every 6 months based on clinical evaluation; pediatric variations provided.

    This section lists the payer’s coverage criteria framework: each medication/indication entry specifies a Maximum Dosing Regimen (route, dose, frequency and any age/weight bands). Coverage is available when the requested dose, frequency, route and duration are at or below the listed maximum for the stated diagnosis and patient age/weight. Providers must document the diagnosis and any weight/age used to calculate mg/kg doses and should reference the effective date when applicable.

    Requests that exceed the stated maximum dosing regimen for the product/diagnosis (for example higher mg/kg, more frequent dosing, or an unlisted route) are not supported by the quantity limits and may be denied or require prior authorization and additional justification. Specific examples include weight- and age-stratified limits for tocilizumab (CRS dosing capped at no more than 4 total doses, per-dose maxima as listed) and infliximab products (maximum maintenance doses up to 10 mg/kg depending on indication).

    For denosumab products the policy distinguishes indications and schedules. Osenvelt (Denosumab-bmwo): for giant cell tumor of bone, hypercalcemia of malignancy and many palliative bone metastases regimens are Subcutaneous 120 mg on days 1, 8, and 15 of month 1, then 120 mg every 4 weeks; for osteopenia/osteoporosis in systemic mastocytosis the regimen is 60 mg every 6 months. Ospomyv (Denosumab-dssb) dosing for osteoporosis and some oncology-related prevention indications is listed as 60 mg every 6 months. Coverage requires adherence to the indication-specific schedule shown.

    When dosing for an indication exceeds the listed maximum regimen the request falls outside the quantity limits. For example, the Cytokine Release Syndrome entry for tocilizumab limits dosing to weight bands with per-dose maxima (e.g., no more than 4 total doses, given at least 8 hours apart and with per-dose mg caps). Similarly, infliximab-type products include explicit upper induction and maintenance caps (up to 10 mg/kg in some scenarios). Exceeding these numeric limits may require prior authorization and will be subject to denial risk.

    Ustekinumab products (IV and SC) have indication- and weight-based regimens. Otulfi (Ustekinumab-aauz) IV induction single doses are weight-tiered (<56 kg = 260 mg; 56–<86 kg = 390 mg; ≥86 kg = 520 mg). Otulfi SC maintenance for Crohn’s disease and other indications uses adult SC schedules (e.g., 90 mg every 8 weeks, with option for every 4 weeks for incomplete response) and distinct initial/maintenance schemes for plaque psoriasis and psoriatic arthritis by age/weight band. Coverage requires matching the route and weight/age band specified for the indication.

    Exceeding the listed maximum dosing regimens may affect authorization and payment. Infliximab entries (Remicade, Renflexis, Inflectra) specify induction and maintenance ceilings (for example initial 5 mg/kg on weeks 0, 2, 6 with maximum induction or maintenance up to 10 mg/kg depending on indication and response). Requests proposing higher per-dose mg/kg, more frequent maintenance intervals than listed, or unlisted induction schedules are inconsistent with these quantity limits and may be denied or require documented justification and prior authorization review.

    IV immune globulin (IVIG) products are included with many diagnosis-specific maximum regimens. Examples across products include CIDP induction and maintenance (initial 2 g/kg divided over 2–5 days then maintenance 1 g/kg every 3 weeks), solid-organ transplant allosensitization regimens (up to 3 g/kg divided over 2–5 days, max 1 g/kg/day), and Stevens–Johnson syndrome/TEN regimens (up to 3 g/kg per course). Use at doses or frequencies above the listed IVIG maxima is not supported without additional justification and may be considered not medically necessary.

    Coverage of IVIG products requires that dosing and frequency match the product- and diagnosis-specific entries. Privigen, Panzyga, Gamunex-C, Gammagard/Gammaked/Gammaplex and other IVIG brands each list maximum regimens per diagnosis (for example, Privigen and Panzyga commonly use 2 g/kg per treatment divided over 2–5 days for many autoimmune indications, with maintenance schedules noted where applicable). Requests that exceed those brand-specific limits may be denied or require prior authorization with supporting documentation.

    Provider requests that exceed maximum dosing regimens—either total course amounts, per-dose mg/kg caps, or frequency limits—are at risk for denial or will require prior authorization review. The document frames coverage as conditional on adherence to the listed maximums for each medication/diagnosis pair; deviations should be justified in the clinical record and submitted with any authorization request.

    When submitting authorization requests for IVIG or other specialty agents, include documentation of diagnosis, patient weight/age (for weight-based dosing), planned dose and frequency, and the product name and effective date referenced. Many IVIG indications require explicit induction versus maintenance dosing (for example, CIDP initial 2 g/kg divided over 2–5 days, then maintenance 1 g/kg every 3 weeks), so supporting notes in the medical record should align with the table entry.

    For denosumab products, oncology and bone indications have different schedules and total exposure implications. For example, Osenvelt lists a loading schedule of 120 mg on days 1, 8, 15 then 120 mg every 4 weeks for giant cell tumor of bone and oncologic uses; Prolia/Ospomyv-style regimens for osteoporosis use 60 mg every 6 months. These differences affect supply requests and authorizations; verify the indication to select the correct maximum regimen.

    Otulfi (ustekinumab IV/SC) dosing is indication- and route-specific; IV dosing uses single weight-tiered amounts (<56 kg = 260 mg; 56–<86 kg = 390 mg; ≥86 kg = 520 mg), while SC maintenance for adults commonly uses 90 mg every 8 weeks (with option to increase to every 4 weeks for incomplete response). Requests must match the route and weight band shown for the diagnosis to be covered under these quantity limits.

    The policy provides numerous examples where coverage requires both a listed diagnosis and adherence to the maximum dosing regimen. For biologics such as tocilizumab and abatacept (Orencia), dosing differs by indication and age/weight band (for example Orencia IV for acute GVHD prophylaxis uses 10 mg/kg in ≥6 years up to a maximum of 1000 mg on specific transplant days). Prior authorization submissions should mirror the exact diagnosis-specific regimen listed.

    Infliximab products and biosimilars carry explicit induction and maintenance caps that vary by indication and age group. Inflectra and Remicade entries show initial induction doses (commonly 5 mg/kg on weeks 0, 2, 6) with maximum induction or maintenance allowances up to 10 mg/kg and, for incomplete response, intervals that may shorten (e.g., every 4 weeks). Coverage and quantity limits are tied to these numeric ceilings.

    IVIG entries emphasize both total course amounts and per-day maxima where applicable (for example some transplant or SJS/TEN entries allow up to 3 g/kg divided over 2–5 days with a per-day cap of 1 g/kg). These numeric constraints should be applied when adjudicating supply requests to determine if the request is within the stated maximum dosing regimen.

    Brand-specific IVIG examples illustrate similar patterns across products: Gamunex‑C entries list regimens such as 400 mg/kg dosing schedules for pediatric indications and courses up to 3 g/kg for severe dermatologic toxicities. When multiple regimen options appear for a single diagnosis (product variants or pediatric vs adult dosing), the provider should apply the product-specific line that matches the requested product and patient characteristics.

    For rituximab products (Riabni, Rituxan) the table lists many oncology and autoimmune schedules with explicit per-dose and frequency constraints (e.g., common regimens of 375 mg/m² weekly or 1000 mg dosing patterns for certain autoimmune indications). Use beyond the documented frequency or dose (for example more frequent weekly dosing than allowed) may not be supported by these quantity limits and would need justification for prior authorization.

    The document does not explicitly label separate "Not Medically Necessary" statements for most entries; however, it consistently indicates that dosing above the listed maximum regimens is not supported. Therefore, use at doses, frequencies, or for diagnoses not listed in the product entries may be considered outside the quantity limits and would require additional review.

    IVIG overuse or requests exceeding per-course maximums (e.g., total grams per treatment or per-day caps) are specifically highlighted by multiple product entries. Examples across Privigen/Panzyga/Gamunex‑C/Gammagard show common maxima such as 2 g/kg per treatment for many autoimmune indications and up to 3 g/kg courses for severe conditions; exceeding these will likely require prior authorization and clinical justification.

    Where weight- or age-based dosing applies, providers must document the patient’s measured weight and age used to determine the mg/kg or weight-band dose (for example to compute tocilizumab or ustekinumab doses). Failure to provide weight/age supporting evidence can impede authorization when the regimen is weight-tiered.

    Numerical exceedances have explicit implications: orders above per-dose mg caps (e.g., tocilizumab per-dose maxima of 800 mg for CRS weight tiers or giant cell arteritis caps) or above maintenance ceilings (such as infliximab maintenance > 10 mg/kg) are inconsistent with these limits and may be denied unless appropriately justified with clinical documentation.

    IVIG use beyond the listed frequencies (for example retreat intervals shorter than those specified or higher cumulative monthly exposure) is identified as potential overuse and may trigger payer review. Examples in the table make clear the usual maintenance intervals (e.g., CIDP maintenance 1 g/kg every 3 weeks) and typical retreat intervals for other diagnoses.

    Some product entries include explicit effective dates (many show Effective 1/1/2026); when present, authorization requests should reference the effective date line for the product/diagnosis to ensure the applicable maximum dosing regimen is applied.

    For IV or single-dose weight-tiered biologic administrations (such as IV ustekinumab/Imuldosa or Pyzchiva IV), the policy lists discrete weight bands with single-dose amounts (for example <56 kg = 260 mg; 56–<86 kg = 390 mg; ≥86 kg = 520 mg). These single-dose weight bands govern coverage for IV induction dosing and must be applied exactly when adjudicating requests.

    Otulfi/ustekinumab entries include both IV single-dose weight bands and SC maintenance schedules; coverage requires selecting the regimen that corresponds to the route and indication: IV weight-banded single-dose induction or SC schedules such as 90 mg every 8 weeks for maintenance (with 4‑week option for incomplete response).

    Dosing exceedance implications are consistent across agent classes: if the requested regimen would result in cumulative exposure, per-dose mg, or frequency greater than the table’s maximum, the request is outside the specified quantity limits and may require prior authorization review or be denied. Examples include denosumab schedules (120 mg loading plus q4w maintenance versus 60 mg q6 months), infliximab upper mg/kg caps, and IVIG per-course maxima.

    When multiple products treat similar diagnoses (e.g., several IVIG brands), coverage is tied to the product-specific line and its maximum dosing regimen. Providers should ensure the requested brand and regimen correspond to a listed entry — otherwise the request may be treated as beyond the quantity limits for that product and require justification.

    Osenvelt and Ospomyv entries illustrate that the same active ingredient may have different dosing schedules by indication (e.g., oncologic/palliative loading vs osteoporosis maintenance). Confirm the indication when matching the request to the correct maximum dosing regimen.

    Where weight-band tables are used (ustekinumab/pyzchiva entries), the policy requires weight to determine the single IV dose; for SC maintenance dosing providers should document the chosen interval (e.g., every 8 weeks vs every 4 weeks for incomplete response).

    IVIG dosing limits repeatedly show both per-course totals and per-day caps; adjudicators should apply both constraints (for example a 3 g/kg course divided over 2–5 days with a max of 1 g/kg/day). Requests that would exceed either the total course or the per-day cap are outside the listed maximum dosing regimens.

    Throughout the document, exceeding the documented maximum dosing regimens (dose, frequency, route, or age/weight band) is explicitly identified as a basis for denial or requirement for prior authorization review. Providers should align supply and authorization requests to the product- and diagnosis-specific entries to avoid denials.

    Coding — Product and Billing References

    No billing codes listed in excerptmixed
    No codes listed
    Medications listed (names only)mixed
    Actemra (Tocilizumab)Actemra (Tocilizumab)
    Adcetris (Brentuximab vedotin)Adcetris (Brentuximab vedotin)
    Alyglo (Immune Globulin Intravenous)Alyglo (Immune Globulin Intravenous)
    Alymsys (Bevacizumab-maly)Alymsys (Bevacizumab-maly)
    Aralast NPAralast NP
    AscenivAsceniv
    BivigamBivigam
    BKEMV (Eculizumab-aaeb)BKEMV (Eculizumab-aaeb)
    Botox (OnabotulinumtoxinA)Botox (OnabotulinumtoxinA)
    Byooviz (Ranibizumab-nuna)Byooviz (Ranibizumab-nuna)
    1–10 of 12
    1/2
    Products referenced (not billing codes)mixed
    Gammagard S/DGammagard S/D (IVIG product)
    GammakedGammaked (IVIG product)
    GammaplexGammaplex (IVIG product)
    Flebogamma DIFFlebogamma DIF (IVIG product)
    BivigamBivigam (IVIG product)
    PrivigenPrivigen (IVIG product)
    IVIG product names listedNDC | mixed
    BivigamBivigam Immune Globulin Intravenous (Human)
    Flebogamma DIFFlebogamma DIF Immune Globulin Intravenous (Human)
    GammaplexGammaplex Immune Globulin Intravenous (Human)
    Gammagard S/DGammagard S/D Immune Globulin Intravenous (Human)
    GammakedGammaked Immune Globulin Intravenous (Human)
    PrivigenPrivigen Immune Globulin Intravenous (Human)
    Products and branded biologics in this excerptmixed
    Infliximab-dyybInflectra (Infliximab-dyyb) — dosing for Ulcerative Colitis and Uveitis
    Bevacizumab-nwgdJobevne (Bevacizumab-nwgd) — multiple oncology and ophthalmology indications
    Denosumab-bbdzJubbonti (Denosumab-bbdz) — breast cancer, osteoporosis, prostate cancer dosing
    Ado-trastuzumab emtansineKadcyla — dosing for breast cancer and NSCLC
    Trastuzumab-annsKanjinti (Trastuzumab-anns) — multiple oncology indications and dosing schedules
    PembrolizumabKeytruda (Pembrolizumab) — multiple oncology indications and dosing schedules
    AlemtuzumabLemtrada (Alemtuzumab) — multiple sclerosis dosing
    RanibizumabLucentis/Byooviz/Cimerli (Ranibizumab products) — ophthalmology indications
    Bevacizumab-awwbMvasi (Bevacizumab-awwb) — parallels Jobevne dosing entries
    inv-76: Maximum doses for Tocilizumab in CRS
    CRS total dose limitNo more than 4 total IV doses for Cytokine Release Syndrome, administered at least 8 hours apart
    Per-dose max for <30 kg12 mg/kg per dose (up to a maximum of 800 mg)
    Per-dose max for >=30 kg8 mg/kg per dose (up to a maximum of 800 mg)
    Minimum intervalDoses must be given at least 8 hours apart
    inv-77: Age/weight dosing strata examples
    Pediatric small weight strata example>=2 years and <30 kg — dosing differs from >=30 kg for several indications (e.g., CRS, JIA)
    Adult vs pediatric age thresholdsExamples use age cutoffs such as >=2 years, >=6 years, >=12 years, and >=18 years
    Common weight breakpointMany entries use <30 kg versus >=30 kg or <56 kg / 56–<86 kg / >=86 kg for weight-tiered dosing
    inv-78: BKEMV (Eculizumab-aaeb) weight/age dosing thresholds
    Adult initial/maintenance (aHUS/gMG example)Adults: initial 900 mg weekly x4 doses; maintenance 1200 mg every 2 weeks starting week 5
    Pediatric ≥40 kgInitial 900 mg weekly x4; maintenance 1200 mg q2w starting week 5
    Pediatric 30–<40 kgInitial 600 mg weekly x2; maintenance 900 mg every 2 weeks starting week 3
    Pediatric 20–<30 kgInitial 600 mg weekly x2; maintenance 600 mg every 2 weeks starting week 3
    Pediatric 10–<20 kgInitial 600 mg weekly x1; maintenance 300 mg every 2 weeks starting week 2
    Pediatric 5–<10 kgInitial 300 mg weekly x1; maintenance 300 mg every 3 weeks starting week 2
    inv-79: Botox maximum cumulative doses and intervals
    Adult cumulative maxAdults: 400 Units maximum cumulative in a 12‑week interval when treating one or more indications
    Per-treatment examplesChronic migraine: 155 Units per treatment; Adult urinary incontinence due to neurologic condition: 200 Units per treatment
    Pediatric caps<18 years: weight-based caps (e.g., 10 Units/kg up to 340 Units cumulative per 12‑week interval)
    Retreatment intervalMay re-treat no sooner than every 12 weeks for most indications (some indications specify 6 months)
    inv-80: Dysport upper/lower limb total per treatment
    Adult total per treatment (upper/lower limb)≥18 years: up to 1500 Units total for upper and lower limb combined per treatment (up to 1000 U for upper limb; up to 1500 U for lower limb)
    Retreatment intervalMay retreat no sooner than every 12 weeks
    Pediatric weight‑based example≥2 to <18 years and <33.33 kg: 30 Units/kg total for upper+lower limb per treatment
    inv-81: CIDP dosing threshold
    CIDP initial total doseInitial: 2 g/kg total (divided over 2–5 consecutive days)
    CIDP maintenance intervalMaintenance: 1 g/kg divided over 1–2 days every 3 weeks
    RouteIntravenous administration for both initial and maintenance regimens
    inv-82: CIDP initial dose
    CIDP initial regimen (detail)2 g/kg divided over 2 to 5 consecutive days
    Typical useGiven as the initial course for CIDP before transition to maintenance dosing
    Documentation requirementWeight must be documented to calculate the mg/kg dosing
    inv-83: CIDP maintenance dose
    CIDP maintenance regimen (detail)1 g/kg divided over 1 to 2 consecutive days every 3 weeks
    FrequencyEvery 3 weeks as maintenance after initial 2 g/kg course
    Maximum per-day constraintMaintenance doses typically limited to 1 g/kg per day when divided
    inv-84: Weight tiers for IV ustekinumab (Imuldosa IV)
    IV ustekinumab single-dose weight tiers<56 kg = 260 mg once; 56 to <86 kg = 390 mg once; ≥86 kg = 520 mg once
    Indications exampleListed for Imuldosa IV in Crohn's disease and related indications
    Effective dateEffective 1/1/2026 (as shown in source)
    inv-85: Hyqvia dosing
    Hyqvia maintenance dosingHyqvia (SC) — 1 g/kg every 3 weeks after initial ramp-up for primary immunodeficiency
    RouteSubcutaneous with recombinant human hyaluronidase
    IndicationChronic Inflammatory Demyelinating Polyneuropathy (CIDP) listed as an indication in the excerpt
    inv-86: Age-based dosing thresholds
    Age categories used across entriesExamples in the document include <2 years, >=2 years, >=6 years, >=12 years, and >=18 years for age‑based dosing distinctions
    ApplicationAge thresholds determine which weight bands or fixed adult doses apply (e.g., tocilizumab, infliximab, pembrolizumab)
    Documentation notePatient age must be documented when age-based dosing is specified
    inv-87: Weight bands for pegfilgrastim
    Pegfilgrastim weight bands≥45 kg; 31–<45 kg; 21–<31 kg; 10–<21 kg; <10 kg
    Typical adult dose≥18 years: 6 mg once per chemotherapy cycle (or 6 mg once for certain indications)
    Pediatric dosing varies by weightSpecific mg doses per week for ARS or other indications depend on weight band (see source)
    inv-88: Weight bands for Pyzchiva IV
    Pyzchiva IV weight bands<56 kg = 260 mg once; 56–<86 kg = 390 mg once; ≥86 kg = 520 mg once
    IndicationsListed for Pyzchiva IV in immune checkpoint inhibitor-related toxicity and ulcerative colitis among others
    Effective dateEffective 1/1/2026 (as shown in source)
    inv-89: Pyzchiva SC maintenance/adjusted dosing
    Pyzchiva SC maintenance dosing (adults)Adults: 90 mg every 8 weeks; may increase to 90 mg every 4 weeks for incomplete response
    Pediatric/weight-based SC regimensPediatric initial and maintenance regimens use mg/kg or higher fixed doses per weight band for certain indications (see product entries)
    RouteSubcutaneous for maintenance dosing
    inv-90: Maximum dosing thresholds (Infliximab, Rituximab examples)
    Infliximab maximumsInfliximab products may be used up to 10 mg/kg (induction/maintenance depending on indication); some indications allow 10 mg/kg every 4 weeks for incomplete response
    Rituximab typical dosing rangeRituximab dosing commonly described as 375 mg/m² up to regimens using 1000 mg (or 500–1000 mg) depending on indication and schedule
    Induction vs maintenanceInfliximab entries specify induction (weeks 0,2,6) and maintenance intervals (every 4–8 weeks) with max induction sometimes 10 mg/kg

    Provider Actions — Authorization, Documentation, and Denial Risk

    Prior Authorization

    Request prior authorization consistent with listed dosing limits

    Prior authorization is implied by the presence of specified maximum dosing regimens for specialty medications; providers should request authorization consistent with the diagnosis‑specific dose limits shown.

    Prior Authorization

    Align requests with the listed diagnosis‑specific dosing

    Ensure prior authorization requests align with the product‑and‑diagnosis dosing shown (route, dose, frequency and any age/weight bands) and reference the effective date where applicable.

    Prior Authorization

    Request PA for quantity/dose exceptions above limits

    If requesting doses that exceed the tabled maximum dosing regimens, submit a prior authorization request for a quantity exception and justify why the higher dose is needed.

    Note

    Quantity limits are listed; no PA procedure shown here

    This document lists maximum dosing regimens for specialty medications but does not provide explicit prior‑authorization procedure or code instructions in the excerpt.

    Prior Authorization

    Obtain prior authorization for specialty medications when required

    Prior authorization is implied for specialty medications when coverage is governed by these maximum dosing regimens; obtain authorization when required by payor rules or when dosing requires verification.

    Prior Authorization

    Seek prior authorization for IVIG with product, indication, and dosing

    For IVIG products, prior authorization is implied and requests should specify the IVIG product, indication, and confirm the dosing matches the listed IVIG regimens.

    Prior Authorization

    Request PA consistent with table‑specified quantity limits

    Prior authorization is required for requests that must adhere to the quantity limits in this document; submit approvals consistent with the listed route, dose, frequency, and age/weight bands.

    Prior Authorization

    Prior authorization required for medications in this table

    Inclusion in the Medical Specialty Medication Quantity Limits table implies prior authorization is required for coverage consistent with the listed maximum dosing regimens.

    Prior Authorization

    Ensure PA matches the listed diagnosis‑specific dosing

    Prior authorization requests must reflect the diagnosis‑specific maximum dosing regimen (dose, route, frequency, age/weight strata) as listed for the medication.

    Prior Authorization

    Include diagnosis and dosing limits in PA requests

    Prior authorization is implied for specialty medication dosing; provide the diagnosis, indicated dosing schedule, and confirm the request does not exceed the listed maximum regimen.

    Prior Authorization

    Align requests with the maximum dosing regimens

    Align prior authorization and supply requests with the maximum dosing regimens (route, dose, frequency, age/weight details) shown for the product and indication.

    Prior Authorization

    Obtain PA for specialty medication dosing per table

    Prior authorization is implied for specialty medication dosing; request authorization consistent with the listed dose, route, frequency, and indication.

    Prior Authorization

    Provide diagnosis and dosing schedule for PA of specialty meds

    When requesting specialty medications, include the diagnosis and dosing schedule consistent with the listed maximum regimen to support prior authorization.

    Prior Authorization

    Submit PA when dosing exceeds payer’s maximums

    If dispensing or requesting doses above the payer's stated maximum dosing regimens per indication and route, submit a prior authorization for the dosing above limits.

    Prior Authorization

    Adhere to the listed induction and maintenance dosing regimens

    Adhere to the listed maximum induction and maintenance dosing regimens (route, age/weight bands and schedule) when requesting coverage and prior authorization.

    Note
    Step Therapy

    No step therapy specified in this excerpt

    No step‑therapy or sequencing requirements are specified in the provided excerpt.

    Step Therapy

    Step therapy not specified in this segment

    The document does not specify step‑therapy rules or required prior agents for sequencing in this segment.

    Note
    Note
    Note
    Note
    Step Therapy

    Step therapy not specified

    No step therapy or agent‑sequencing requirements are specified in this document segment.

    Step Therapy

    No step therapy requirements listed

    No step therapy requirements are specified in the provided excerpt.

    Note
    Note
    Step Therapy

    Step therapy not specified (none listed)

    No step therapy requirements are specified in the provided segments.

    Note
    Note
    Note
    Documentation Required

    Document diagnosis and dosing to support PA

    Provider documentation should support that the diagnosis and dosing align with the product‑specific maximum dosing regimens listed (route, dose, frequency, age/weight bands and effective date where applicable).

    Documentation Required

    Support requests with the listed diagnosis, dosing and effective date

    Authorization or dispensing should reference the diagnosis‑specific maximum dosing regimen and effective date for the product when submitting requests.

    Documentation Required

    Provide required dosing details (dose, frequency, age/weight)

    Include diagnosis, route, age/weight strata, dosing regimen (dose and frequency), and effective date in the request as shown in the entries.

    Note
    Documentation Required

    Document dose and schedule to match listed maximums

    Document the exact dose and schedule to show that dosing and frequency match the listed maximum dosing regimens for the indicated diagnosis.

    Documentation Required

    Document indication and planned dosing regimen

    Prescribers should document the indication/diagnosis and the planned dosing regimen (dose, frequency, route, duration) consistent with the product‑specific maximum dosing regimens.

    Documentation Required

    Ensure medical record supports diagnosis and dosing

    The medical record must support the diagnosis and dosing consistent with the product‑specific maximum dosing regimens (e.g., diagnosis linked to the stated mg/kg or g/kg regimen).

    Documentation Required

    Document patient age and indication for age‑limited dosing

    When dosing is age‑specific (e.g., Kawasaki syndrome), document patient age and indication to support the dosing regimen.

    Documentation Required

    Document patient weight and age for weight‑based dosing

    When dosing is weight‑based, document patient weight and age to support the selected mg/kg or weight‑band dosing within the listed maximum regimen.

    Documentation Required

    Include dose, route, frequency, and diagnosis in documentation

    Include dose, route, frequency, and diagnosis in the prior authorization or prescription to demonstrate adherence to the listed Maximum Dosing Regimen for the specific product and indication.

    Documentation Required

    Document diagnosis and exact dosing regimen in PA

    Prescriptions or prior authorization requests should document the diagnosis and the dosing regimen (route, dose, frequency, age/weight basis) matching the listed maximum dosing for the medication.

    Documentation Required

    Support PA with medication, diagnosis, and adherence to maximum regimen

    Provide the medication, diagnosis, and evidence that the requested dosing adheres to the maximum dosing regimen (route, dose, frequency, duration) when seeking authorization.

    Documentation Required

    Document weight/age when applicable to support dosing

    Document the diagnosis and the patient’s weight/age when dosing is weight‑ or age‑based to support the selected maximum dosing regimen.

    Documentation Required

    Supply patient weight and indication for weight‑band dosing

    When dosing by weight band (e.g., mg/kg or weight tiers), supply the patient's weight and the indication to support dosing within the listed maximum regimen.

    Documentation Required

    Document effective date when applicable

    Document the effective date shown for entries (e.g., Effective 1/1/2026) when it is relevant to the request or authorization.

    Denial Risk

    Claims exceeding listed maximums may be denied

    Claims for doses that exceed the listed maximum dosing regimens for a specified diagnosis may be denied.

    Denial Risk

    Requests above quantity limits are inconsistent with policy

    Requests exceeding the listed maximum dosing regimens (quantity limits) for a given diagnosis and product would be inconsistent with the limits provided and may be denied.

    Denial Risk

    Quantity‑limit exceedance may be denied without justification

    Requests exceeding the listed maximum dosing regimens for the specified diagnosis, age/weight, route, or frequency may be denied; provide justification if exceeding limits is necessary.

    Note
    Denial Risk

    Exceeding listed maximums may trigger denial or require justification

    Requests that exceed the listed maximum dosing regimens (higher mg/kg, greater units, or more frequent dosing than specified) would trigger quantity‑limit denial or require justification.

    Denial Risk

    Exceeding product‑specific maximums may prompt denial

    Requests exceeding product‑specific maximum dosing regimens for the diagnosis/indication may be subject to denial or quantity‑limit enforcement.

    Note
    Denial Risk

    Dose over limit may be denied

    Requests exceeding the maximum dosing regimens listed for the diagnosis (e.g., doses above specified g/kg or frequency) may be denied.

    Denial Risk

    Dose exceeding maximum may be denied

    Requests exceeding the listed maximum dosing regimens for a medication/diagnosis may be denied.

    Denial Risk

    Quantity limit exceedance may trigger denial or require justification

    Prescriptions or requests exceeding the stated Maximum Dosing Regimen for the specified diagnosis and product may trigger denial or require justification.

    Denial Risk

    Exceeding maximum dosing may trigger denial

    Requests exceeding the listed maximum dosing regimens (dose, frequency, or route) for the specified diagnosis may trigger denial.

    Denial Risk

    IV/other dosing beyond limits may be denied

    Requests exceeding the listed maximum dosing regimens (e.g., IV dosing beyond stated grams/kg or frequency) may be inconsistent with the quantity limits and could trigger denial.

    Denial Risk

    Prescriptions exceeding listed maximums may trigger quantity‑limit denials

    Prescribed dosing that exceeds the listed maximum dosing regimens for a given diagnosis and route may trigger quantity‑limit denials.

    Denial Risk

    Exceeding listed regimen may trigger denial or PA review

    Requests exceeding the listed maximum dosing regimen (dose or frequency) for a medication/indication may trigger denial or require prior authorization review.

    Denial Risk

    Dose exceedance risk — may result in denial

    Requests exceeding the specified maximum dosing regimens (e.g., doses above listed maximum maintenance or induction doses) may trigger denial.

    Background — Scope and Policy Context

    Background: This policy segment enumerates specialty medications relevant to immunology, rheumatology, neurology, oncology, transplant, and ophthalmology and establishes maximum dosing regimens by product and diagnosis (often weight‑ or age‑based). Many entries indicate an effective date (commonly Effective 1/1/2026), and coverage is conditioned on adherence to the listed regimen.

    Definitions and Key Terms

    inv-152: Maximum Dosing Regimen — definition
    DefinitionMaximum Dosing Regimen = the policy-specified maximum permitted route, dose (often mg/kg), and frequency for the medication when used for the listed diagnosis.
    ScopeApplies per medication, diagnosis, and patient age/weight strata as listed in the policy table
    Includes induction/maintenanceMay include distinct induction and maintenance dosing schedules where specified
    inv-153: Diagnosis/Diagnoses — definition
    DefinitionDiagnosis/Diagnoses = the specific clinical indication(s) for which the medication's maximum dosing regimen is specified
    UsageEach entry ties a product to one or more listed diagnoses with associated maximum dosing regimens
    Documentation implicationProvider requests should reference the listed diagnosis to match dosing limits
    inv-154: Maximum Dosing Regimen (alternate reference)
    Definition (alternate)Maximum Dosing Regimen = the highest dosing schedule specified by Aetna for a drug by route and diagnosis (includes mg/kg or fixed mg, frequency, and treatment intervals)
    ExamplesShown across IV, SC, and intravitreal routes with weight/age bands
    Effective dateEntries frequently include effective dates (e.g., Effective 1/1/2026) for specified regimens
    inv-155: Maximum Dosing Regimen (alternate reference)
    Definition (alternate)The highest approved frequency and dose listed for a drug for a specified diagnosis, route, and patient age/weight in this document segment
    Patient strataAge and weight strata determine applicable maximums (e.g., <30 kg vs ≥30 kg)
    EnforcementRequests exceeding these maximums may trigger denial or require prior authorization per policy notes
    inv-156: aHUS — definition in context
    aHUS definitionaHUS = Atypical Hemolytic Uremic Syndrome as used in the BKEMV (eculizumab-aaeb) dosing entry
    ContextaHUS dosing is specified in weight/age tiers with induction and maintenance schedules
    Clinical implicationProvider must supply patient weight/age to apply the correct tiered regimen
    inv-157: Maximum Dosing Regimen (alternate reference)
    Definition (alternate)Maximum Dosing Regimen = the highest routine dosing schedule and route of administration listed for a given medication and diagnosis (e.g., mg/kg, units, frequency, retreat intervals)
    Examples includedIncludes per‑dose caps (e.g., 800 mg for tocilizumab) and cumulative limits (e.g., 400 Units Botox per 12 weeks)
    PurposeUsed to bound coverage and quantity limits in the policy
    inv-158: Initial vs Maintenance dosing — definition
    Initial vs MaintenanceInitial dosing refers to a higher induction total dose (e.g., CIDP 2 g/kg over 2–5 days) followed by maintenance dosing (e.g., 1 g/kg every 3 weeks)
    Typical patternInduction schedules often span several consecutive days; maintenance recurs at specified intervals
    DocumentationProvider should document which phase (initial vs maintenance) is being requested
    inv-159: IVIG products — definition / examples
    Examples of IVIG productsGammagard S/D, Gammaked, Gammaplex (also Privigen, Panzyga, Octagam listed elsewhere)
    RouteThese are intravenous immune globulin (IVIG) preparations used for multiple immunologic and neurologic indications
    Dose patternsCommon regimens include 2 g/kg initial courses and 1 g/kg maintenance schedules depending on indication
    inv-160: Initial and Maintenance dosing (CIDP example)
    CIDP initial vs maintenance (definition)Initial: 2 g/kg divided over 2–5 consecutive days; Maintenance: 1 g/kg divided over 1–2 consecutive days every 3 weeks
    Example productsThis initial/maintenance format is shown for Gammaplex, Gammagard Liquid, and similar IVIG products
    ImplicationCoverage checks must consider whether a request is for initial induction or ongoing maintenance
    inv-161: Routes — definition of administration routes referenced
    Routes definedRoutes cited include Intravenous (IV), Subcutaneous (SC), Intrathecal/Intraventricular (IT/IVT) where applicable
    Route impactDosing regimens and maximums differ by route (e.g., intravitreal mg per eye vs IV mg/kg)
    Administration implicationsProvider requests must specify route to match the listed Maximum Dosing Regimen
    inv-162: Weight tiers — definition/example
    Weight tiers definitionSome regimens are stratified by weight categories (e.g., <56 kg; 56–<86 kg; ≥86 kg) to determine single IV dose amounts
    ApplicationUsed for agents like IV ustekinumab and Pyzchiva IV to select correct dose
    Provider requirementPatient weight must be provided to apply the correct tier
    inv-163: Maximum Dosing Regimen — consolidated definition
    Consolidated definitionMaximum Dosing Regimen = the highest dose and frequency permitted by the policy for a product/diagnosis, including induction and maintenance where specified
    Enforcement noteDose, frequency, route, and patient age/weight band are all checked against the listed maximum
    Effective datesSome entries include effective dates (e.g., Effective 1/1/2026) which should be referenced
    inv-164: weight-based pediatric categories — definition/example
    Pediatric weight categoriesWeight-based pediatric categories used for agents like pegfilgrastim: ≥45 kg; 31–<45 kg; 21–<31 kg; 10–<21 kg; <10 kg
    ImplicationDosing in pediatrics is often specified by weight band rather than fixed mg
    ExamplePegfilgrastim uses these bands for ARS and febrile neutropenia prevention
    inv-165: Maximum Dosing Regimen — alternate definition
    Alternate definitionMaximum Dosing Regimen = the specified administration route, dose (often weight-based), dosing schedule, and maximum frequency/duration for the medication and indication
    Coverage roleUsed to bound allowed quantity and to inform prior authorization and denial risk
    ExamplesIncludes mg/kg, g/kg, unit limits, and retreatment intervals as listed in entries
    inv-166: Maximum Dosing Regimen — alternate definition
    Consolidated purposeMaximum Dosing Regimen = the highest allowed dose and schedule specified by diagnosis, route, and patient age/weight band for each product
    Provider actionProviders must align requests with these limits to obtain coverage
    ExamplesEntries include IV, SC, and intravitreal maximums by diagnosis and band
    inv-167: Intravitreal — definition
    Intravitreal definitionIntravitreal = administration route into the vitreous cavity of the eye (used for Pavblu, Ahzantive, etc.)
    Dose contextIntravitreal doses are listed as mg per affected eye with initial loading and maintenance schedules
    Coverage noteDosing frequency for intravitreal agents often expressed as every ~28 days or approximately every 25 days
    inv-168: mg/kg — definition
    mg/kg definitionmg/kg = milligrams of drug per kilogram of patient body weight; used to calculate weight-based doses listed in many entries
    RequirementPatient weight must be documented to determine allowable dose under mg/kg regimens
    ExamplesCommon mg/kg regimens include 8 mg/kg (tocilizumab), 5 mg/kg (infliximab), 2 g/kg (IVIG) depending on indication
    inv-169: Induction and Maintenance — definition
    Induction and Maintenance definitionInduction = initial dosing schedule (e.g., weeks 0, 2, and 6); Maintenance = ongoing dosing interval after induction (e.g., every 8 weeks or every 3 weeks)
    ExamplesInfliximab/Inflectra: induction at weeks 0,2,6 then maintenance q8w; Rituximab: weekly x4 induction for some autoimmune conditions then maintenance every 6 months
    Provider implicationAuthorization requests should indicate whether induction or maintenance dosing is requested
    Policy Summary
    PayerAetna
    PolicyMedical Specialty Medication Quantity Limits — Maximum Dosing Regimens
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionRequest prior authorization consistent with the diagnosis‑specific maximum dosing regimen and document the diagnosis, patient weight/age, and planned dosing schedule.
    SourceLink
    On This Page
    Coverage Criteria — Maximum Dosing RegimensCoding — Product and Billing ReferencesProvider Actions — Authorization, Documentation, and Denial RiskBackground — Scope and Policy ContextDefinitions and Key Terms
    as listed per regimen

    Many regimens specify different induction/maintenance doses by age/weight

    as listed per regimen

    Many regimens specify different dosing by age/weight

    Sourced from Bivigam entries (chunk 55)

    Bivigam - Stiff-Person Syndrome: Route: Intravenous; Maximum dosing regimen: 2 g/kg divided over 2–5 consecutive days every month.2 g/kg monthly

    Sourced from Bivigam entry (chunk 55)

    Bivigam - Systemic Lupus Erythematosus (SLE): Route: Intravenous; Maximum dosing regimen: 2 g/kg divided over 2–5 consecutive days every 4 weeks.2 g/kg q4w

    Sourced from Bivigam entry (chunk 55)

    Bivigam - Tetanus treatment/prophylaxis: Route: Intravenous; Maximum dosing regimen: 400 mg/kg once if tetanus immune globulin not available.400 mg/kg once

    Sourced from Bivigam entry (chunk 55)

    Bivigam - Toxic Necrotizing Fasciitis (Group A Streptococcus): Route: Intravenous; Maximum dosing regimen: 2 g/kg divided over 1–5 consecutive days.2 g/kg per course

    Sourced from Bivigam entry (chunk 55)

    Bivigam - Toxic Shock Syndrome: Route: Intravenous; Maximum dosing regimen: 2 g/kg divided over 1–5 consecutive days.2 g/kg per course

    Sourced from Bivigam entry (chunk 55)

    Bivigam - Varicella prophylaxis: Route: Intravenous; Maximum dosing regimen: 400 mg/kg once as soon as possible and within 10 days after exposure.400 mg/kg once within 10 days

    Sourced from Bivigam entry (chunk 55)

    BKEMV (Eculizumab-aaeb) - aHUS/gMG/PNH examples: Weight/age-based IV loading and maintenance regimens provided (e.g., aHUS/adult: initial 900 mg weekly x4 then 1200 mg q2w maintenance; PNH: initial 600 mg weekly x4 then 900 mg q2w), per product table.see eculizumab weight/age dosing tiers

    Sourced from Epysqli/Epysqli entries (chunk 78)

    Denosumab (Bomyntra/Osenvelt/Ospomyv) examples: Giant cell tumor of bone/hypercalcemia/palliative bone metastases: SC 120 mg days 1,8,15 then 120 mg q4w; osteoporosis/systemic mastocytosis: SC 60 mg every 6 months (product‑specific biosimilar entries apply).120 mg loading then q4w or 60 mg q6m depending on indication

    Sourced from denosumab entries (chunks 29,218–219)

    Sourced from Daxxify/Dysport entries (chunk 73,75)

    Entyvio (Vedolizumab) — example: Crohn's/Ulcerative colitis/ICPI toxicity: IV 300 mg on weeks 0, 2, and 6 then every 8 weeks (maintenance where specified).300 mg induction at weeks 0,2,6; maintenance q8w

    Sourced from Entyvio entries (chunk 78)

    Eculizumab (Epysqli/Epiginna) — example: aHUS adults: initial 900 mg weekly x4 then 1200 mg q2w maintenance; weight/age tiers provided for pediatric bands per product table.weight/age-based loading and maintenance regimens

    Sourced from Epysqli entries (chunk 78)

    IVIG (Flebogamma/Flebogamma DIF) — example: Kawasaki syndrome: <18 years 2 g/kg single dose (repeat if needed); Measles prophylaxis: 400 mg/kg once within 6 days after exposure; CIDP: initial 2 g/kg divided over 2–5 days then maintenance 1 g/kg q3w (product‑specific variations noted).per‑indication mg/kg regimens

    Sourced from Flebogamma, Flebogamma DIF entries (chunks 89,97)

    Varicella prophylaxis: Gammagard Liquid: 400 mg/kg once as soon as possible and within 10 days after exposure.400 mg/kg single dose

    Effective 1/1/2026 (chunk 105)

    Sourced from Kanjinti entries (chunks 168–169)

    Multiple oncologic indications with IV dosing examples such as 240 mg q2w or 480 mg q4w; weight/age‑based initial induction dosing examples and pediatric adjustments are provided per indication.
    indication-specific regimens

    Sourced from Opdivo entries (chunk 206)

    Orencia (Abatacept) — examples: Acute GVHD prophylaxis: IV ≥6 yrs 10 mg/kg (up to 1000 mg) on day -1 then days 5, 14, 28; Chronic GVHD: initial 10 mg/kg weeks 0,2,4 then 10 mg/kg q4w; JIA/RA/psoriatic arthritis: weight/age banded IV regimens with specified initial and maintenance doses (see product entries).age/weight and indication-specific

    Sourced from Orencia entries (chunks 216–217)

    Sourced from Orencia entry (chunk 216)

    Orencia — JIA/RA/psoriatic arthritis weight bands: IV dosing by age/weight (examples): JIA ≥6 yrs <75 kg initial 10 mg/kg wks 0,2,4 then q4w; adults <60 kg initial 500 mg wks 0,2,4 then 500 mg q4w; 60–<101 kg initial 750 mg then 750 mg q4w; ≥101 kg initial 1000 mg then 1000 mg q4w.weight bands per entry

    Sourced from Orencia entries (chunks 216–217)

    Sourced from Ospomyv entry (chunk 219)

    age/weight bands and q12w maintenance

    Sourced from Otulfi SC entries (chunks 221–222)

    Sourced from Panzyga entry (chunk 224)

    Panzyga — Kawasaki syndrome: Pediatric <18 years: 2 g/kg single dose; repeat if needed.2 g/kg single dose (pediatric)

    Sourced from Panzyga entry (chunk 227)

    Panzyga — Maternal neonatal hemochromatosis prophylaxis: Maternal: IV 1 g/kg every week beginning week 18 of gestation until delivery.1 g/kg weekly from wk 18 to delivery

    Sourced from Panzyga entry (chunk 229)

    Panzyga — Measles/Varicella prophylaxis: Measles: 400 mg/kg once within 6 days after exposure; Varicella prophylaxis: 400 mg/kg once within 10 days after exposure (product timing noted per entry).timing specified

    Sourced from Panzyga entries (chunks 228,233)

    up to 10 mg/kg induction/maintenance per indication

    Sourced from Remicade/Renflexis entries (chunks 250–254)

    Infliximab — Hidradenitis Suppurativa / other indications: Up to 10 mg/kg every 4 weeks (may include induction on weeks 0, 2, 6) for select indications.10 mg/kg q4w

    Sourced from Remicade/Renflexis entries (chunks 250–255)

    induction max 10 mg/kg; maintenance max 10 mg/kg q8w

    Sourced from Remicade entry (chunk 252)

    Sourced from Renflexis entries (chunks 254–256)

    Renflexis — Plaque psoriasis / Psoriatic arthritis / Hidradenitis Suppurativa: IV induction and maintenance dosing with maximum maintenance dosing up to 10 mg/kg every 4 weeks for some indications.10 mg/kg q4w max maintenance

    Sourced from Renflexis entries (chunks 254–255)

    Sourced from Riabni entries (chunks 260–261)

    Cryoglobulinemia / membranous nephropathy: IV options include 1000 mg every 2 weeks or 375 mg/m² weekly depending on regimen.1000 mg q2w or 375 mg/m² weekly

    Sourced from Riabni entries (chunks 260,262)

    Neurologic and autoimmune indications (MS, MG, NMOSD, Sjögren's, SLE, solid organ transplant): IV: 1000 mg dosing regimens with timing constraints (e.g., 1000 mg every 2 weeks or not more frequent than every 14 days for some indications); schedules vary by diagnosis and age.1000 mg with timing constraints

    Sourced from Riabni entries (chunks 262–264)

    Pediatric aggressive mature B‑cell lymphomas: IV ≥6 months to <18 years: 375 mg/m² (frequency/cycle varies; not more frequent than 2 doses in one week).pediatric limits

    Sourced from Riabni pediatric entries (chunk 263)

    induction then maintenance schedules

    Sourced from Rituxan entries (chunks 269–270)

    Pemphigus vulgaris and other autoimmune blistering diseases: IV: ≥18 years: 375 mg/m² weekly x4 per course (may repeat after ≥6 months) OR initial 1000 mg x2 two weeks apart with maintenance dosing options and relapse management schedules per entry.specified induction and maintenance regimens

    Sourced from Rituxan entries (chunk 271)